SAREPTA THERAPEUTICS, INC. Restructuring Costs
SAREPTA THERAPEUTICS, INC. (SRPT) reported Restructuring Costs of $134.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. restructuring costs for the quarter ending 2025-09-30 was $134.00K.
- SAREPTA THERAPEUTICS, INC. restructuring costs for the quarter ending 2017-12-31 was $247.00K, a 88.45% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. restructuring costs for the quarter ending 2017-09-30 was $13.00K, a 98.97% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. restructuring costs for the quarter ending 2017-06-30 was $2.52M, a 303.19% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. restructuring costs for fiscal 2025 was $134.00K.
- SAREPTA THERAPEUTICS, INC. restructuring costs for fiscal 2018 was -$2.22M, a 173.58% decline from fiscal 2017.
- SAREPTA THERAPEUTICS, INC. restructuring costs for fiscal 2017 was $3.02M, a 33.80% decline from fiscal 2016.
- SAREPTA THERAPEUTICS, INC. restructuring costs for fiscal 2016 was $4.56M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month | Restructuring Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $134.00K 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $134.00K 10-Q · filed 2025-11-06 | |||
| 2018-12-31 | -$2.22M 10-K · filed 2019-02-28 | |||
| 2017-12-31 | $247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $260.00K derived: sum of 2 quarters · filed 2019-02-28 | $2.78M derived: sum of 3 quarters · filed 2019-02-28 | $3.02M 10-K · filed 2019-02-28 |
| 2017-09-30 | $13.00K 10-Q · filed 2017-11-01 | $2.54M derived: sum of 2 quarters · filed 2017-11-01 | $2.77M 10-Q · filed 2017-11-01 | $4.91M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $2.52M 10-Q · filed 2017-08-03 | $2.76M 10-Q · filed 2017-08-03 | $4.90M derived: sum of 3 quarters · filed 2019-02-28 | $6.16M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $236.00K 10-Q · filed 2017-05-04 | $2.38M derived: sum of 2 quarters · filed 2019-02-28 | $3.64M derived: sum of 3 quarters · filed 2019-02-28 | $4.26M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $3.40M derived: sum of 2 quarters · filed 2019-02-28 | $4.03M derived: sum of 3 quarters · filed 2019-02-28 | $4.56M 10-K · filed 2019-02-28 |
| 2016-09-30 | $1.26M 10-Q · filed 2017-11-01 | $1.89M derived: sum of 2 quarters · filed 2017-11-01 | $2.42M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $626.00K 10-Q · filed 2017-08-03 | $1.16M 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | $533.00K 10-Q · filed 2017-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |